Oral Small Molecule Therapeutics
•254 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (254)
| Company | Market Cap | Price |
|---|---|---|
|
NRXP
NRx Pharmaceuticals, Inc.
NRX-101 is an oral small-molecule therapeutic (D-cycloserine + lurasidone) for bipolar depression.
|
$36.85M |
$1.85
-0.80%
|
|
ANTX
AN2 Therapeutics, Inc.
Epetraborole and AN2-502998 are oral small-molecule therapeutics developed on the company's boron chemistry platform.
|
$36.62M |
$1.33
-0.75%
|
|
VERU
Veru Inc.
Veru's lead asset enobosarm is an oral small molecule therapeutic.
|
$36.50M |
$2.49
+2.89%
|
|
OKUR
OnKure Therapeutics, Inc.
OKUR's lead candidate and pipeline consist of small-molecule therapeutics (PI3Kα inhibitors), consistent with Oral Small Molecule Therapeutics.
|
$35.45M |
$2.61
-0.38%
|
|
SCYX
SCYNEXIS, Inc.
SCYNEXIS's ibrexafungerp is a lead oral small-molecule therapeutic, fitting the 'Oral Small Molecule Therapeutics' category.
|
$32.49M |
$0.77
-0.65%
|
|
BTAI
BioXcel Therapeutics, Inc.
BXCL501 is a small-molecule drug delivered as an oral dissolving film; fits 'Oral Small Molecule Therapeutics'.
|
$29.26M |
$2.04
-1.69%
|
|
LTRN
Lantern Pharma Inc.
LP-300, LP-184, LP-284 are small-molecule oncology therapeutics candidates, aligning with the oral small molecule therapeutics category.
|
$27.75M |
$2.52
-1.95%
|
|
AYTU
Aytu BioPharma, Inc.
AYTU's core ADHD portfolio comprises oral small-molecule therapeutics (Adzenys XR-ODT, Cotempla XR-ODT) and Karbinal ER, fitting the 'Oral Small Molecule Therapeutics' category.
|
$26.54M |
$2.63
+0.96%
|
|
BOLD
Boundless Bio, Inc.
Lead programs BBI-355, BBI-825, and BBI-940 are oral small-molecule therapeutics (CHK1 inhibitor, RNR inhibitor, and kinesin degrader), representing the core product category of Oral Small Molecule Therapeutics.
|
$25.52M |
$1.15
+0.44%
|
|
MIRA
MIRA Pharmaceuticals, Inc.
Ketamir-2 is a novel oral small-molecule therapeutic targeting neuropathic pain, aligning with the 'Oral Small Molecule Therapeutics' category.
|
$24.22M |
$1.25
-1.97%
|
|
THAR
Tharimmune, Inc.
TH104 is a transmucosal buccal film formulation of nalmefene for prophylaxis, representing Oral Small Molecule Therapeutics.
|
$23.83M |
$4.74
-5.58%
|
|
ATHA
Athira Pharma, Inc.
ATH-1105 is described as an orally available, brain-penetrant small molecule developed for ALS, fitting the 'Oral Small Molecule Therapeutics' tag.
|
$23.58M |
$6.87
+22.24%
|
|
DARE
Daré Bioscience, Inc.
Oral Small Molecule Therapeutics: Sildenafil Cream is a small-molecule pharmacologic product, albeit topical, aligning with this category of therapeutics.
|
$22.92M |
$1.69
+0.90%
|
|
APLM
Apollomics, Inc.
Lead products are oral small molecule therapeutics targeting MET/c-MET pathways in cancer.
|
$22.63M |
N/A
|
|
VYNE
VYNE Therapeutics Inc.
VYN202 is an oral BD2-selective small molecule therapeutic, aligning with Oral Small Molecule Therapeutics.
|
$19.59M |
$0.59
-0.66%
|
|
CVKD
Cadrenal Therapeutics, Inc. Common Stock
Cadrenal's tecarfarin is described as a novel oral small-molecule therapeutic, directly aligning with the 'Oral Small Molecule Therapeutics' tag.
|
$16.99M |
$8.31
+0.18%
|
|
ANEB
Anebulo Pharmaceuticals, Inc.
Anebulo's lead candidate selonabant is a small molecule therapeutic (initially oral) targeting cannabis-induced CNS effects; thus aligns with Oral Small Molecule Therapeutics.
|
$16.42M |
$0.37
-7.59%
|
|
PALI
Palisade Bio, Inc.
PALI-2108 is an orally administered small molecule therapeutic, matching the Oral Small Molecule Therapeutics tag.
|
$15.87M |
$1.74
-0.29%
|
|
JUNS
Jupiter Neurosciences, Inc.
Direct product category: orally administered small-molecule therapeutics based on a resveratrol platform (JOTROL).
|
$15.78M |
$0.44
-2.27%
|
|
ALLR
Allarity Therapeutics, Inc.
Stenoparib is a small-molecule therapeutic (PARP/WNT inhibitor), a core drug candidate.
|
$15.35M |
$1.04
-0.48%
|
|
APLT
Applied Therapeutics, Inc.
Govorestat is an oral small-molecule therapeutic (Aldose Reductase Inhibitor), fitting the Oral Small Molecule Therapeutics category.
|
$14.83M |
$0.11
+4.37%
|
|
TPST
Tempest Therapeutics, Inc.
Lead programs are oral, small molecule therapeutics (amezalpat TPST-1120 and TPST-1495).
|
$13.81M |
$3.15
-0.16%
|
|
KAPA
Kairos Pharma, Ltd.
KROS 301 is described as a tumor-targeting small molecule and checkpoint inhibitor, fitting oral small molecule therapeutics.
|
$13.06M |
$0.64
+2.21%
|
|
CRIS
Curis, Inc.
Emavusertib is an orally available, small-molecule therapeutic targeting IRAK4/FLT3.
|
$12.87M |
$1.01
-1.94%
|
|
LIPO
Lipella Pharmaceuticals Inc.
LP-310 is a liposomal tacrolimus formulation delivered orally, aligning with the Oral Small Molecule Therapeutics category.
|
$12.20M |
$0.31
|
|
ELTP
Elite Pharmaceuticals, Inc.
Products highlighted include oral, small-molecule therapeutics such as methotrexate and analgesics, indicating a major focus on oral generics.
|
$11.45M |
$0.41
|
|
TRAW
Traws Pharma, Inc.
Ratutrelvir and tivoxavir marboxil are oral small-molecule antivirals, including a bird-flu–targeted influenza therapy.
|
$11.44M |
$1.57
-3.09%
|
|
BIVI
BioVie Inc.
Bezisterim is described as an orally administered small molecule therapeutic targeting inflammation-driven insulin resistance in neurodegenerative diseases, aligning with 'Oral Small Molecule Therapeutics'.
|
$10.93M |
$1.35
-6.55%
|
|
COCP
Cocrystal Pharma, Inc.
Lead candidates CC-42344, CDI-988, and CC-31244 are oral formulations, aligning with the 'Oral Small Molecule Therapeutics' category.
|
$10.57M |
$1.02
-0.97%
|
|
EPIX
ESSA Pharma Inc.
The company develops oral small molecule therapeutics, masofaniten belongs to this class; qualifies as a major product category.
|
$8.93M |
$0.20
|
|
ITRM
Iterum Therapeutics plc
ORLYNVAH is an oral small molecule antibiotic (sulopenem) that the company is launching commercially.
|
$7.52M |
$0.17
+0.83%
|
|
SCNX
Scienture Holdings, Inc.
Arbli is an oral small-molecule therapeutic delivered as a liquid formulation, aligning with the Oral Small Molecule Therapeutics theme.
|
$6.94M |
$0.44
-1.77%
|
|
KTTA
Pasithea Therapeutics Corp.
PAS-4.00 is described as an oral small molecule therapeutic, representing Pasithea's core drug product.
|
$6.56M |
$0.85
+1.50%
|
|
ADIL
Adial Pharmaceuticals, Inc.
AD04 is a small-molecule therapeutic candidate (likely oral) for Alcohol Use Disorder, matching Oral Small Molecule Therapeutics.
|
$6.45M |
$0.28
-3.65%
|
|
PCSA
Processa Pharmaceuticals, Inc.
NGC-Cap is based on modifying an existing chemotherapy (capecitabine) to improve safety/efficacy, aligning with the Oral Small Molecule Therapeutics category as part of the NGC pipeline.
|
$5.64M |
$3.01
+7.50%
|
|
ADXN
Addex Therapeutics Ltd
Addex's core product category is oral small-molecule therapeutics (allosteric modulators including GABAB PAMs and mGluR modulators).
|
$5.60M |
N/A
|
|
SBFM
Sunshine Biopharma, Inc.
Lead antiviral PL4 is orally active in models, aligning with oral small-molecule therapeutics.
|
$5.47M |
$1.17
-4.88%
|
|
APRE
Aprea Therapeutics, Inc.
APRE's lead products are oral small-molecule therapeutics (WEE1 and ATR inhibitors) for cancer, fitting Oral Small Molecule Therapeutics.
|
$5.34M |
$0.90
+2.67%
|
|
CPHI
China Pharma Holdings, Inc.
Oral small molecule therapeutics, including tablets/capsules like Roxithromycin dispersible tablets.
|
$5.07M |
$1.55
-0.26%
|
|
IBO
Impact BioMedical Inc.
Linebacker/Equivir are small-molecule therapeutics with potential oral administration pathways, aligning with Oral Small Molecule Therapeutics.
|
$5.04M |
$0.75
+81.18%
|
|
APM
Aptorum Group Limited
Repurposed and other small-molecule therapeutics in the pipeline align with the Oral Small Molecule Therapeutics investable theme.
|
$4.63M |
$0.80
-3.27%
|
|
BIXT
Bioxytran, Inc.
ProLectin-M is an oral antiviral candidate; fits the Oral Small Molecule Therapeutics category as a major product line.
|
$3.58M |
$0.04
|
|
CANF
Can-Fite BioPharma Ltd.
Company focuses on orally bioavailable small molecule therapeutics targeting A3AR, including Piclidenoson and Namodenoson.
|
$2.99M |
$5.25
-12.79%
|
|
JAGX
Jaguar Health, Inc.
Jaguar Health focuses on crofelemer-based therapies delivered orally, aligning with the Oral Small Molecule Therapeutics category.
|
$2.54M |
$1.18
+3.98%
|
|
ACXP
Acurx Pharmaceuticals, Inc.
Lead product ibezapolstat is an oral small-molecule antibiotic for CDI, aligning with the 'Oral Small Molecule Therapeutics' investable theme.
|
$2.41M |
$1.53
+0.99%
|
|
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
Lead candidate Ropidoxuridine is described as an oral small-molecule therapeutic, with additional small-molecule HDAC inhibitors in the pipeline.
|
$1.98M |
$1.79
-2.97%
|
|
BICX
BioCorRx Inc.
BioCorRx is actively commercializing Lucemyra, an FDA-approved oral small molecule therapeutic for opioid withdrawal, expanding direct product sales.
|
$1.69M |
$0.40
|
|
ENVB
Enveric Biosciences, Inc.
EB-3.00 and related assets are small-molecule therapeutics, a major product category for early-stage biotech pipelines.
|
$1.45M |
$5.21
-2.71%
|
|
GRTX
Galera Therapeutics, Inc.
Classify as oral small molecule therapeutics (SOD mimetics and NOS inhibitors are small‑molecule drugs).
|
$1.31M |
$0.02
|
|
NLSP
NLS Pharmaceutics AG
NLSP's lead products Quilience and Nolazol are oral, extended-release small-molecule therapeutics based on mazindol.
|
$894150 |
$0.79
-72.35%
|
|
CDT
CDT Equity Inc.
AZD1656/AZD5658 are small-molecule therapeutics licensed for development.
|
$398063 |
$1.01
-2.88%
|
|
SLRX
Salarius Pharmaceuticals, Inc.
Lead programs include oral small molecule therapeutics (seclidemstat) and a small molecule TPD candidate (SP-3164), both classified as small molecule cancer therapies.
|
$397571 |
$0.74
-5.36%
|
|
CMND
Clearmind Medicine Inc.
CMND-100 is an oral small-molecule therapeutic candidate, categorizing the company under Oral Small Molecule Therapeutics.
|
$160038 |
$1.18
-0.84%
|
|
EMMA
Emmaus Life Sciences, Inc.
Endari is an oral small-molecule therapeutic (L-glutamine) marketed by Emmaus Life Sciences for sickle cell disease.
|
$14040 |
$0.01
|
Showing page 3 of 3 (254 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
